Manager TitleAgeSince
President 63 2010-05-26
Director TitleAgeSince
Director/Board Member 63 2010-03-25
Director/Board Member 85 2011-05-31
Director/Board Member 79 2013-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.16%+2.68%+51.09% 58.7B
-2.39%+0.50%+3.41%+31.33% 48.36B
-8.22%-9.22%+290.86%+633.84% 43.05B
-0.52%-1.99%+27.38%+28.06% 42.48B
-4.60%-3.38%-1.26%+100.63% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-2.54%-4.08%-12.59%-15.01% 23.93B
-2.45%-9.06%-38.97%+302.90% 22.22B
Average -4.20%-2.63%+35.96%+141.24% 42.9B
Weighted average by Cap. -5.27%-1.88%+42.36%+133.84%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-